David B. Smith

2.9k total citations
59 papers, 1.8k citations indexed

About

David B. Smith is a scholar working on Accounting, Hepatology and Infectious Diseases. According to data from OpenAlex, David B. Smith has authored 59 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Accounting, 16 papers in Hepatology and 14 papers in Infectious Diseases. Recurrent topics in David B. Smith's work include Auditing, Earnings Management, Governance (18 papers), Hepatitis C virus research (16 papers) and HIV/AIDS drug development and treatment (13 papers). David B. Smith is often cited by papers focused on Auditing, Earnings Management, Governance (18 papers), Hepatitis C virus research (16 papers) and HIV/AIDS drug development and treatment (13 papers). David B. Smith collaborates with scholars based in United States, United Kingdom and South Korea. David B. Smith's co-authors include Michael Ettredge, Soo Young Kwon, Paul Tanyi, Paul Zarowin, Klaus Klumpp, Vincent Lévêque, Julian Symons, Isabel Nájera, Joseph A. Martin and Mary S. Stone and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

David B. Smith

57 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David B. Smith United States 23 659 472 397 332 318 59 1.8k
Hans Sjögren Sweden 28 119 0.2× 99 0.2× 361 0.9× 57 0.2× 134 0.4× 142 4.0k
Michael Joyce Canada 31 120 0.2× 711 1.5× 694 1.7× 25 0.1× 566 1.8× 86 3.8k
Christian Hofmann Germany 24 332 0.5× 250 0.5× 97 0.2× 189 0.6× 41 0.1× 160 2.4k
David W. Mullins United States 34 1.9k 2.8× 38 0.1× 148 0.4× 760 2.3× 44 0.1× 90 4.9k
Joel Owen United States 19 105 0.2× 197 0.4× 110 0.3× 77 0.2× 15 0.0× 73 1.3k
David Emanuel United States 26 554 0.8× 267 0.6× 1.1k 2.9× 301 0.9× 45 0.1× 74 3.1k
Li-Yu Chen China 17 86 0.1× 110 0.2× 219 0.6× 55 0.2× 107 0.3× 54 861
James Fisher United States 21 66 0.1× 171 0.4× 245 0.6× 65 0.2× 163 0.5× 79 1.3k
Richard Wilson United Kingdom 29 382 0.6× 157 0.3× 537 1.4× 156 0.5× 2 0.0× 106 2.2k
Dong‐Jae Kim South Korea 19 143 0.2× 120 0.3× 143 0.4× 370 1.1× 5 0.0× 58 1.8k

Countries citing papers authored by David B. Smith

Since Specialization
Citations

This map shows the geographic impact of David B. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David B. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David B. Smith more than expected).

Fields of papers citing papers by David B. Smith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David B. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David B. Smith. The network helps show where David B. Smith may publish in the future.

Co-authorship network of co-authors of David B. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of David B. Smith. A scholar is included among the top collaborators of David B. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David B. Smith. David B. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Amblard, Franck, Zhe Chen, John Wiseman, et al.. (2023). Synthesis and evaluation of highly potent HBV capsid assembly modulators (CAMs). Bioorganic Chemistry. 141. 106923–106923. 5 indexed citations
2.
Jekle, Andreas, Suping Ren, April Kinkade, et al.. (2023). Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models. International Journal of Molecular Sciences. 24(22). 16274–16274. 5 indexed citations
3.
Kao, C. Cheng, Yuchun Nie, Suping Ren, et al.. (2021). Mechanism of action of hepatitis B virus S antigen transport-inhibiting oligonucleotide polymer, STOPS, molecules. Molecular Therapy — Nucleic Acids. 27. 335–348. 14 indexed citations
4.
Tanyi, Paul, David B. Smith, & Xiaoyan Cheng. (2021). Does firm payout policy affect shareholders’ dissatisfaction with directors?. Review of Quantitative Finance and Accounting. 57(1). 279–320. 7 indexed citations
5.
Cheng, Xiaoyan, et al.. (2020). A path analysis investigation of the relationships between CEO pay ratios and firm performance mediated by employee satisfaction. Advances in Accounting. 48. 100457–100457. 26 indexed citations
6.
Fitzgerald, Megan, Hong Jin, Rajendra K. Pandey, et al.. (2020). Structural requirements for S-antigen transport-inhibiting oligonucleotide polymer inhibition of hepatitis B surface antigen secretion. Journal of Hepatology. 73. S876–S877. 2 indexed citations
7.
Clarke, Niamh, et al.. (2019). GDPR: an impediment to research?. Irish Journal of Medical Science (1971 -). 188(4). 1129–1135. 35 indexed citations
8.
Smith, David B., et al.. (2018). Financial statement comparability and segment disclosure. Research in Accounting Regulation. 30(2). 103–111. 5 indexed citations
9.
Jin, Zhinan, April Kinkade, Shuvam Chaudhuri, et al.. (2017). Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs. Antiviral Research. 143. 151–161. 38 indexed citations
10.
Tan, Hua, Kenneth J. Shaw, Jérôme Deval, et al.. (2015). P0682 : Preclinical characterization of AL-335, a potent uridine based nucleoside polymerase inhibitor for the treatment of chronic hepatitis C. Journal of Hepatology. 62. S577–S578. 3 indexed citations
11.
Tan, Hui‐Leng, Andreas Jekle, Hyunsoon Kang, et al.. (2013). 1222 IN VITRO RESISTANCE TO ALS-2200, A POTENT NUCLEOTIDE POLYMERASE INHIBITOR FOR THE TREATMENT OF CHRONIC HEPATITIS C. Journal of Hepatology. 58. S496–S496. 1 indexed citations
12.
13.
Brandl, Michael, Xiaoyang Wu, Hong Lei, et al.. (2008). Physicochemical Properties of the Nucleoside Prodrug R1626 Leading to High Oral Bioavailability. Drug Development and Industrial Pharmacy. 34(7). 683–691. 29 indexed citations
14.
Kinsella, Anne R. & David B. Smith. (1998). Tumor Resistance To Antimetabolites. General Pharmacology The Vascular System. 30(5). 623–626. 26 indexed citations
15.
Smith, David B., et al.. (1990). Quantitative distribution of 131I-labelled monoclonal antibodies administered by the intra-ventricular route. European Journal of Cancer and Clinical Oncology. 26(2). 129–136. 11 indexed citations
16.
Smith, David B. & Anthony Howell. (1989). A phase II trial of oral idarubicin plus dibromodulcitol in advanced breast cancer. European Journal of Cancer and Clinical Oncology. 25(1). 141–143. 11 indexed citations
17.
Smith, David B., et al.. (1988). The prognostic significance of X‐ray changes at presentation and reassessment in patients with multiple myeloma. Hematological Oncology. 6(1). 1–6. 25 indexed citations
18.
Letson, G. William, Mathuram Santosham, Raymond Reid, et al.. (1988). Comparison of active and combined passive/ active immunization of Navajo children against Haemophilus influenzae type b. The Pediatric Infectious Disease Journal. 7(11). 747–752. 19 indexed citations
19.
Wagstaff, John, et al.. (1987). A phase I study of recombinant interferon gamma administered by s.c. injection three times per week in patients with solid tumours. Cancer Immunology Immunotherapy. 25(1). 54–8. 16 indexed citations
20.
Smith, David B., et al.. (1984). An investigation of the information content of foreign sensitive payment disclosures. Journal of Accounting and Economics. 6(2). 153–162. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hans Sjögren Breakdown of academic impact, for papers by Michael Joyce Breakdown of academic impact, for papers by Christian Hofmann Breakdown of academic impact, for papers by David W. Mullins Breakdown of academic impact, for papers by Joel Owen Breakdown of academic impact, for papers by David Emanuel Breakdown of academic impact, for papers by Li-Yu Chen Breakdown of academic impact, for papers by James Fisher Breakdown of academic impact, for papers by Richard Wilson Breakdown of academic impact, for papers by Dong‐Jae Kim
Rankless by CCL
2026